

## **Rakovina Therapeutics President to Join Expert Panel at the Fifth Annual DDR, ATR & PARP Inhibitors Summit**

VANCOUVER, British Columbia, Jan. 25, 2022 -- Rakovina Therapeutics Inc. (TSXV:RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce that Prof. Mads Daugaard, Rakovina Therapeutics president and chief scientific officer, has accepted an invitation as an expert panellist at the 5th Digital DDR, ATR & PARP Inhibitors Summit.

The DDR, ATR and PARP Inhibitors Summit brings together industry and academic experts focused on advancing new and novel next-generation DNA-damage repair inhibitors (DDRi). Prof. Daugaard will participate as an expert panellist alongside senior scientists from AstraZeneca and the National Brain Tumor Society to discuss insights and future directions for DDRi in the treatment of cancer.

The Conference is being held virtually January 25<sup>th</sup> – 27<sup>th</sup>, 2022. Registrants can stream all three days of conference events and engage with the panellists during livestream events.

“I am pleased to represent Rakovina Therapeutics at this important meeting, said Prof. Daugaard. I look forward to the opportunity to discuss our work alongside of distinguished industry and academic colleagues as we all work to advance highly effective cancer treatments with fewer side effects to benefit patients across a range of tumor types.”

The DDR, ATR & PARP Inhibitors Summit is an industry-led forum that reflects progress in DDR therapies. This conference looks to address the 3 key challenges DDRi developers are striving to address:

- Translatability of preclinical models
- Awareness/understanding/utilization of methodologies & imaging technology
- DDR tumor biomarkers & outcome measures

This is a notable biopharma conference for research teams developing inhibitors of specific DDR targets in either monotherapy or in combination, to treat predictable, identifiable, DDR-defective cancer indications.

Further information and registration details regarding the virtual conference can be found at <https://ddr-inhibitors-summit.com/>.

### **About Rakovina Therapeutics Inc.**

About Rakovina Therapeutics Inc. Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response (DDR) technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information may be found at [www.rakovinatherapeutics.com](http://www.rakovinatherapeutics.com)

### **Additional Information**

*The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.*

### **Notice regarding forward-looking statements:**

This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at [www.sedar.com](http://www.sedar.com).

Contact:

**Rakovina Therapeutics Inc.**

David Hyman

Chief Financial Officer

Email: [info@rakovinatherapeutics.com](mailto:info@rakovinatherapeutics.com)

**Investor Relations Contact**

[IR@rakovinatherapeutics.com](mailto:IR@rakovinatherapeutics.com)

**Media Contact**

[MEDIA@rakovinatherapeutics.com](mailto:MEDIA@rakovinatherapeutics.com)